Objective:
To present the real-world efficacy and safety of faricimab in neovascular age-related macular degeneration (nAMD) based on the TRUCKEE study results over 4.5 years.
Approach:
- Study Design: The TRUCKEE study was a real-world study involving over 3,600 eyes and more than 2,900 patients, focusing on the effects of faricimab without industry sponsorship.
Key Findings:
- Faricimab demonstrated sustained anatomic improvements in both treatment-naïve and previously treated populations.
- Patients switching from aflibercept to faricimab experienced nearly 2-week extension in treatment intervals after 9 injections.
- Treatment-naïve patients achieved treatment intervals extending to about 10 weeks with faricimab.
- The safety profile of faricimab included a low rate of intraocular inflammation and endophthalmitis.
Interpretation:
Limitations:
- The study involved a specific patient population and may not be generalizable to all nAMD patients.
- The comfort level of physicians with treatment intervals may influence results.
Conclusion:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.